文献速递浆细胞疾病

靶向多发性骨髓瘤中的高唾液酸化是增强NK细胞介导的肿瘤反应的新方法

Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses.
PubMed 文献 · Blood Adv · 2022-01-01

该研究探讨高唾液酸化在多发性骨髓瘤(MM)细胞逃避自然杀伤(NK)细胞免疫监视中的作用。研究发现原代MM细胞和MM细胞系高表达Siglec-7的唾液酸衍生配体(Siglec-7L),其中PSGL-1是MM中主要的Siglec-7L;使用唾液酸酶和唾液酸转移酶抑制剂(SIA)去唾液酸化可增强NK细胞对MM细胞的细胞毒性,并增加CD38的检测;去唾液酸化还可增强达雷妥尤单抗处理后NK细胞对CD38+ MM细胞的细胞毒性;低CD38表达的MM细胞经全反式维甲酸(ATRA)、SIA和达雷妥尤单抗处理可引发强效NK细胞毒性反应;Siglec-7敲除可增强NK细胞对Siglec-7L+ MM细胞的细胞毒性。

要点

  • 原代MM细胞和MM细胞系高表达Siglec-7L,PSGL-1是MM中主要Siglec-7L。
  • 唾液酸酶和SIA去唾液酸化增强NK细胞对MM细胞的细胞毒性。
  • 去唾液酸化增加CD38检测,并增强达雷妥尤单抗处理后NK细胞对CD38+ MM细胞的细胞毒性。

核心结论

  • MM细胞去唾液酸化是增强NK细胞抗MM疗效的有前景的新方法,可与前线治疗联合引发强效抗MM反应。

研究设计与样本

  • 本研究为体外研究,探索高唾液酸化在促进MM细胞逃避NK细胞中的作用。

主要发现

  • 原代MM细胞和MM细胞系强表达Siglec-7的唾液酸衍生配体(Siglec-7L)。
  • MM细胞裂解物相互作用组实验显示PSGL-1是MM中主要的Siglec-7L。
  • 使用唾液酸酶和唾液酸转移酶抑制剂(SIA)去唾液酸化强烈增强NK细胞介导的对MM细胞的细胞毒性。
  • MM细胞去唾液酸化导致CD38检测增加。
  • 去唾液酸化增强达雷妥尤单抗处理后NK细胞对CD38+ MM细胞的细胞毒性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Abnormal glycosylation is a hallmark of cancer, and the hypersialylated tumor cell surface facilitates abnormal cell trafficking and drug resistance in several malignancies, including multiple myeloma (MM). Furthermore, hypersialylation has also been implicated in facilitating evasion of natural killer (NK) cell-mediated immunosurveillance but not in MM to date. In this study, we explore the role of hypersialylation in promoting escape from NK cells. We document strong expression of sialic acid-derived ligands for Siglec-7 (Siglec-7L) on primary MM cells and MM cell lines, highlighting the possibility of Siglec-7/Siglec-7L interactions in the tumor microenvironment. Interactomics experiments in MM cell lysates revealed PSGL-1 as the predominant Siglec-7L in MM. We show that desialylation, using both a sialidase and sialyltransferase inhibitor (SIA), strongly enhances NK cell-mediated cytotoxicity against MM cells. Furthermore, MM cell desialylation results in increased detection of CD38, a well-validated target in MM. Desialylation enhanced NK cell cytotoxicity against CD38+ MM cells after treatment with the anti-CD38 monoclonal antibody daratumumab. Additionally, we show that MM cells with low CD38 expression can be treated with all trans-retinoic acid (ATRA), SIA and daratumumab to elicit a potent NK cell cytotoxic response. Finally, we demonstrate that Siglec-7KO potentiates NK cell cytotoxicity against Siglec-7L+ MM cells. Taken together, our work shows that desialylation of MM cells is a promising novel approach to enhance NK cell efficacy against MM, which can be combined with frontline therapies to elicit a potent anti-MM response.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Daly J, Sarkar S, Natoni A, et al. Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses. Blood Adv. 2022. PMID: 35294519. doi:10.1182/bloodadvances.2021006805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。